[go: up one dir, main page]

US9011908B2 - Progesterone solutions for increased bioavailability - Google Patents

Progesterone solutions for increased bioavailability Download PDF

Info

Publication number
US9011908B2
US9011908B2 US12/752,629 US75262910A US9011908B2 US 9011908 B2 US9011908 B2 US 9011908B2 US 75262910 A US75262910 A US 75262910A US 9011908 B2 US9011908 B2 US 9011908B2
Authority
US
United States
Prior art keywords
capsule
weight
acid
progesterone
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US12/752,629
Other languages
English (en)
Other versions
US20100255085A1 (en
Inventor
Zhi Liu
Saujanya L. Gosangari
Dana S. Toops
Aqeel Fatmi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Patheon Softgels Inc
Original Assignee
Banner Life Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12/752,629 priority Critical patent/US9011908B2/en
Application filed by Banner Life Sciences LLC filed Critical Banner Life Sciences LLC
Assigned to BANNER PHARMACAPS, INC. reassignment BANNER PHARMACAPS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TOOPS, DANA S., GOSANGARI, SAUJANYA L., LIU, ZHI, FATMI, AQEEL
Publication of US20100255085A1 publication Critical patent/US20100255085A1/en
Assigned to MORGAN STANLEY SENIOR FUNDING INC., AS COLLATERAL AGENT reassignment MORGAN STANLEY SENIOR FUNDING INC., AS COLLATERAL AGENT SECURITY AGREEMENT Assignors: BANNER PHARMACAPS INC.
Assigned to UBS AG, STAMFORD BRANCH, AS COLLATERAL AGENT reassignment UBS AG, STAMFORD BRANCH, AS COLLATERAL AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BANNER PHARMACAPS INC.
Assigned to BANNER PHARMACAPS INC. reassignment BANNER PHARMACAPS INC. TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENT RIGHTS Assignors: MORGAN STANLEY SENIOR FUNDING, INC.
Assigned to BANNER LIFE SCIENCES LLC reassignment BANNER LIFE SCIENCES LLC CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: BANNER PHARMACAPS INC.
Assigned to UBS AG, STAMFORD BRANCH, AS COLLATERAL AGENT reassignment UBS AG, STAMFORD BRANCH, AS COLLATERAL AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BANNER LIFE SCIENCES LLC
Publication of US9011908B2 publication Critical patent/US9011908B2/en
Application granted granted Critical
Assigned to BANNER LIFE SCIENCES LLC reassignment BANNER LIFE SCIENCES LLC RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: UBS AG, STAMFORD BRANCH
Assigned to BANNER PHARMACAPS INC., BANNER LIFE SCIENCES LLC reassignment BANNER PHARMACAPS INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: UBS AG, STAMFORD BRANCH
Assigned to BANNER LIFE SCIENCES LLC reassignment BANNER LIFE SCIENCES LLC CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVEYANCE PREVIOUSLY RECORDED AT REEL: 034359 FRAME: 872. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Assignors: BANNER PHARMACAPS INC.
Assigned to PATHEON SOFTGELS INC reassignment PATHEON SOFTGELS INC NUNC PRO TUNC ASSIGNMENT (SEE DOCUMENT FOR DETAILS). Assignors: BANNER LIFE SCIENCES LLC
Assigned to CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS SUCCESSOR AGENT reassignment CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS SUCCESSOR AGENT NOTICE OF SUCCESSION OF AGENCY FOR PATENT SECURITY INTEREST PREVIOUSLY RECORDED AT REEL/FRAME (032403/0790) Assignors: UBS AG, STAMFORD BRANCH, AS PRIOR AGENT
Assigned to BANNER PHARMACAPS INC. reassignment BANNER PHARMACAPS INC. RELEASE (REEL 032403 / FRAME 0790) Assignors: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Definitions

  • This invention is in the field of capsule fill materials containing hydrophobic drugs, particularly hydrophobic sex hormones, such as progesterone, which exhibit increased bioavailability when administered orally.
  • Sex hormones are a class of compounds produced by the testicles, ovaries, brain, placenta, and/or adrenal glands, which play a major role in reproduction and sexual identity.
  • One class of sex hormones is the steroidal hormones. Steroidal hormones are typically hydrophobic, having low solubility in aqueous solution, and low bioavailability in vivo.
  • Progesterone is a C-21 steroidal sex hormone involved in the female menstrual cycle, pregnancy (supports gestation) and embryogenesis of humans and other species. Progesterone belongs to a class of hormones called progestogens, and is the major naturally occurring human progestogen. Like other steroids, progesterone consists of four interconnected cyclic hydrocarbons. Progesterone is hydrophobic, having an aqueous solubility of 0.007 ⁇ 0.0 mg/ml. Progesterone is biosynthesized from pregnenolone, a derivative of cholesterol.
  • Progesterone and its analogues can be used to treat a variety of medical conditions, including acute diseases or disorders, as well as chronic diseases and disorders associated with long-term declines of natural progesterone levels.
  • progesterone is poorly absorbed when administered orally.
  • PROMETRIUM® a commercially available progesterone formulation, is an attempt to overcome the poor oral bioavailability of progesterone (see the package insert for PROMETRIUM®).
  • PROMETRIUM® the progesterone is micronized and suspended in an edible oil, such as peanut oil.
  • clinical trials involving PROMETRIUM® showed significant interpatient and intrapatient variability. For example, a clinical trial involving postmenopausal women who were administered PROMETRIUM® once a day for five days resulted in the mean pharmacokinetic parameters listed in Table1 (see the package insert for PROMETRIUM®).
  • WO99/08666 by Glaxo Group, Ltd. describes solutions containing a therapeutically effective amount of an aza steroid and a fatty acid ester of glycerol or propylene glycol.
  • the aza steroid is present in a concentration from 0.0025 to 2.5% by weight of the solution, more preferably from 0.025 to 1.5% by weight of the solution, with a dose of 0.1 to 10 mg.
  • Aza steroids are synthetically derived steroids, not steroidal sex hormones. Further, the concentration of the steroid is very low, i.e., less than 2.5% by weight of the fill.
  • the softgel capsule contains an internal, non-aqueous liquid phase containing a solution or suspension of a single, hydrophobic pharmacologically active agent effective to treat a dermatological disorder and one or more fatty acids or derivatives thereof, such as omega-3 fatty acids, DHA, docosapentaenoic acid, tetracosapentaenoic acid, tetracosahexaenoic acid, monounsaturated fatty acids, polyunsaturated fatty acids, saturated fatty acids, trans fatty acids, derivatives thereof, and mixtures thereof.
  • Suitable classes of active agent include steroids.
  • the '686 application does not disclose or suggest fill materials containing steroidal sex hormones, such as progesterone dissolved in a fatty acid solvent.
  • WO 2006/102157 by Ivax Pharmaceuticals S.R.O. describes soft gelatin capsules that encapsulate a water-insoluble active agent dissolved in a crystallization inhibitor.
  • the inhibitor contains at least one monoacylglycerol compound whose acyl group is a fatty acid residue of 6-18 carbons.
  • the concentration of the inhibitor is from 2 to 10% w/w of the fill (page 6, lines 9-12).
  • the '157 application does not disclose or suggest a capsule containing a steroidal sex hormone dissolved in a fatty acid solvent, wherein the concentration of the fatty acid solvent is at least 50% by weight of the fill material.
  • U.S. Pat. No. 5,645,856 to Lacy, et al. describes a pharmaceutical composition containing progesterone in a carrier system containing a digestible oil and a pharmaceutically acceptable surfactant component for dispersing the oil in vivo.
  • EP 0 750 495 to R.P. Scherer Technologies, Inc. describes a pharmaceutical composition containing a lipophilic surfactant component and a hydrophobic drug dispersed or dissolved in a digestible oil which contains a hydrophilic surfactant, where some or all of the oil is the lipophilic surfactant component.
  • the '856 and '495 patents define “digestible oil” as an oil which is capable of undergoing de-esterification in the presence of pancreatic lipase in vivo under normal physiological conditions.
  • the surfactant component may contain a fatty acid such as oleic acid.
  • the '856 patent describes formulations containing up to 50% by weight of the drug. Although progesterone is included in the list of drugs which may be formulated, the concentration of progesterone in the examples does not exceed about 5% by weight.
  • WO 97/40823 by R.P. Scherer Ltd. describes the '856 patent to Lacy, et al., as achieving a maximum concentration of progesterone of about 4% which requires either a large dosage capsule or requires the dosage to be split into two capsules.
  • the '823 application seeks to address low solubilization of progesterone through pharmaceutical compositions containing a hydrophobic drug, a digestible oil, such as triglycerides or propylene glycol esters of medium chain length (C 8 -C 12 ) and/or long (C 13 -C 22 ) fatty acids, and propylene glycol monolaurate; a lipophilic surfactant containing a glyceride of C 5 to C 10 fatty acid; and a hydrophilic surfactant which is a polyoxyethylene hydrogenated castor oil.
  • the '823 application discloses formulations that preferably do not contain unsaturated components.
  • the '823 application describes progesterone formulations containing up to 6.5% by weight progesterone in solubilized form.
  • U.S. Pat. No. 4,963,540 to Maxson et al. describes pharmaceutical compositions suitable for oral administration containing micronized progesterone dispersed in an oil vehicle which is high in glycerides of polyunsaturated fatty acids.
  • the fill materials can be used to fill capsules, such as softgel capsules.
  • the capsules contain a dose of progesterone from 50-150 mg, particularly 90-110 mg.
  • the oil vehicle is used in an amount ranging from 1.5-2.5 ml per one gram of progesterone.
  • the fill material in the '540 patent is a dispersion, not a solution.
  • compositions containing higher concentrations of a sex hormone such as progesterone, and which exhibit higher oral bioavailability, lower interpatient and intrapatient variability, and do not contain carriers which are unsuitable due to a high prevalence of adverse reactions when ingested.
  • compositions containing a sex hormone such as progesterone, that exhibit: (1) increased oral bioavailability, compared to a formulation containing micronized drug suspended in a carrier; (2) lower interpatient and intrapatient variability compared to a formulation containing micronized drug suspended in a carrier, and (3) higher effective concentrations of the hormone; and methods of making and using thereof.
  • a sex hormone such as progesterone
  • compositions which do not contain a carrier known to cause adverse reactions.
  • hydrophobic active agents such as the sex hormone progesterone
  • the fill materials contain the hydrophobic active agent dissolved in a fatty acid-containing carrier composition.
  • Suitable hydrophobic active agents include sex hormones, such as progesterone, in combination with one or more additional active agents.
  • Exemplary fatty acids include, but are not limited to, oleic acid, linoleic acid, myristoleic acid, palmitoleic acid, arachidonic acid, and combinations thereof.
  • the concentration of the hydrophobic active agent is typically from about 6% to about 50% by weight of the fill material, preferably from 7% to about 40% of the fill material, preferably from about 7% to about 25% by weight of the fill material, more preferably from about 7% to about 20%, more preferably from about 7% to about 15% by weight of the fill material.
  • the sex hormone is progesterone which is present from about 7% to about 15% by weight of the fill material, preferably from about 8% to about 12% by weight of the fill material, more preferably from about 9% to about 11% by weight of the fill material.
  • the dose of progesterone is from about 100 mg to about 300 mg, more preferably from about 100 mg to about 200 mg. In one embodiment, the dose of progesterone is 100 mg, 200 mg, or 300 mg.
  • the concentration of the one or more fatty acids in the carrier composition is from about 60% to about 95% by weight of the fill material, preferably from 60% to about 90% by weigh of the fill materials, more preferably from about 60% to about 85% by weight of the fill material, most preferably from about 60% to about 80% by weight.
  • the one or more fatty acids is oleic acid in a concentration from about 60% to about 95% by weight of the fill material, more preferably from about 65% to about 85% by weight of the fill material.
  • the carrier composition further contains one or more pharmaceutically acceptable organic acids selected from C 1 to C 12 acids.
  • Suitable organic acids include, but are not limited to, lactic acid, acetic acid, glycolic acid, propionic acid, isobutyric acid, butyric acid, isovaleric acid, valeric acid, caproic acid, succinic acid and combinations thereof.
  • the concentration of the one or more organic acids is from about 1 to about 20% by weight of the fill material, preferably from about 2 to about 18% by weight of the fill material, preferably from about 3% to about 15% by weight of the fill material, more preferably from about 5% to about 12% by weight of the fill material, most preferably from about 6% to about 12% by weight of the fill material.
  • the carrier composition also contains one or both of one or more pharmaceutically acceptable alcohols selected from C 1 to C 6 alcohols, and one or more pharmaceutically acceptable mono-, di-, or triesters of medium or long chain fatty acids.
  • Suitable alcohols include, but are not limited to, ethanol, isopropanol, isobutanol, butanol, t-butanol, glycerol, propylene glycol and combinations thereof.
  • the concentration of the alcohol is from about 1 to about 20% by weight of the fill material, preferably from about 2 to about 18% by weight of the fill material, preferably from about 5 to about 15% by weight of the fill material, more preferably from about 6% to about 15% by weight of the fill material, most preferably from about 8% to about 15% by weight of the fill material.
  • Suitable fatty acid esters include, but are not limited to, mono- and diglycerides of capric and caprylic acids; mono-, di-, and triglycerides of coconut oil; glyceryl monooleate, glyceryl monolinoleate; propylene glycol monocaprylate; propylene glycol caprylate; propylene glycol dicaprylocaprate; propylene glycol monolaurate; propylene glycol laurate; polyethoxylated fatty acid esters; polyethylene glycol monostearate; polyoxy stearate; polyethylene glycol hydroxystearate; macrogol hydroxystearate; and combinations thereof.
  • the concentration of the ester is from about 1% to about 40% by weight of the fill material, preferably from about 5% to about 35% by weight of the fill material, preferably from about 10% to about 35% by weight of the fill material, more preferably from about 15% to about 35% by weight of the fill material, most preferably from about 20% to about 35% by weight of the fill material.
  • the fill material optionally further contains one or more additional excipients such as stabilizers, antioxidants, colorants, flavorings, which are typically present in fill formulations for capsules.
  • additional excipients such as stabilizers, antioxidants, colorants, flavorings, which are typically present in fill formulations for capsules.
  • the fill material can be encapsulated in a hard or soft, gelatin or non-gelatin capsule.
  • the capsule may be an enteric capsule, wherein the enteric polymer or polymers is a component of the capsule shell.
  • the capsule can be coated with a modified release coating, such as a delayed release coating, a sustained release coating, or combinations thereof.
  • compositions described herein provide improved dissolution in aqueous media in vitro compared to formulations of hydrophobic drugs suspended in an oil, such as peanut oil.
  • the compositions described herein release at least about 10%, 20%, 30%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the drug in vitro after 5 minutes in 5% SDS in water or at least about 10%, 20%, 30%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the drug in vitro after 15 minutes in 0.5% SDS in water.
  • compositions described herein release at least about 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, or 70% of the drug in vitro in fed state simulated intestinal fluid (FeSSIF) after 24 hours.
  • FeSSIF fed state simulated intestinal fluid
  • Progesterone can be used to support pregnancy in Assisted Reproductive Technology (ART) cycles such as In-vitro Fertilization (IVF).
  • Progesterone can also be used to control anovulatory bleeding, to prepare uterine lining in infertility therapy, and to support early pregnancy. Patients with recurrent pregnancy loss due to inadequate progesterone production may receive progesterone.
  • Progesterone is also used for the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogen tablets and for treatment of secondary amenorrhea.
  • capsules described herein exhibit improved dissolution in aqueous media in vitro compared to formulations containing micronized progesterone suspended in an oil, such as peanut oil, such as commercially available formulations sold under the trademark PROMETRIUM®.
  • an oil such as peanut oil
  • PROMETRIUM® such as commercially available formulations sold under the trademark PROMETRIUM®.
  • capsules (Formulation 5) containing progesterone dissolved in a fatty acid-based carrier containing CAPMUL® PG-8 (27.5% by weight of the composition) released over 90% of the progesterone after 5 minutes in 5% SDS in water compared to PROMETRIUMTNI PROMETRIUM®, which released negligible amounts of progesterone over the same time period.
  • PROMETRIUM® capsules The cumulative release at the end of 24 hours from the fatty acid-containing formulation was about 51% versus less than about 10% from PROMETRIUM®.
  • the improved dissolution in vitro should result in improved bioavailability in vivo compared to micronized progesterone formulations.
  • FIG. 1 is a graph comparing the in vitro release profile of progesterone (percent release) dissolved in an oleic acid-based vehicle and encapsulated in a two-piece hard shell capsule to the in vitro release profile of PROMETRIUM® (micronized progesterone suspended in peanut oil and encapsulated in a softgel capsule) in 5% sodium dodecyl sulfate (SDS) in water as a function of time (minutes) in a USP Apparatus II at 37 ⁇ 0.5° C. and 100 RPM.
  • PROMETRIUM® micronized progesterone suspended in peanut oil and encapsulated in a softgel capsule
  • SDS sodium dodecyl sulfate
  • FIG. 2 is a graph comparing the in vitro release profile of progesterone (percent release) dissolved in oleic acid and encapsulated in a softgel capsule to the in vitro release profile of PROMETRIUM® (micronized progesterone suspended in peanut oil and encapsulated in a softgel capsule) in 0.5% sodium dodecyl sulfate (SDS) in water as a function of time (minutes) in a USP Apparatus II at 37 ⁇ 0.5° C. and 100 RPM.
  • SDS sodium dodecyl sulfate
  • FIG. 3 is a graph comparing the in vitro release profile of progesterone (percent release) dissolved in a mixture of oleic acid, Capmul® PG-8 and ethanol and encapsulated in a softgel capsule to the in vitro release profile of PROMETRIUM® (micronized progesterone suspended in peanut oil encapsulated in a softgel capsule) in deaerated water as a function of time (minutes) in a USP Apparatus II at 37 ⁇ 0.5° C. and 100 RPM.
  • FIG. 4 is a graph comparing the in vitro release profiles (percent released) of progesterone capsules containing oleic acid, lactic acid, ethanol, and Capmul PG-8 and PROMETRIUM® (micronized progesterone suspended in peanut oil encapsulated in a softgel capsule) in Fed State Simulated Intestinal Fluid (FeSSIF) in a USP Apparatus II at 37 ⁇ 0.5° C. and 100 RPM.
  • FeSSIF Fed State Simulated Intestinal Fluid
  • “Sex hormone”, as used herein, refers to chemicals produced by the testicles, ovaries, brain, placenta, and/or adrenal glands, which play a major role in reproduction and sexual identity.
  • One class of sex hormones is the steroidal hormones. Examples of sex hormones include, but are not limited to, progesterone.
  • “Fatty acid”, as used herein, refers to a molecules having the chemical formula R—C( ⁇ O)—OH.
  • the fatty acid may contain one or more additional sites of unsaturation, such as carbon-carbon double bonds, carbon-carbon triple bonds, and combinations thereof.
  • Medium chain fatty acid refers to a natural or synthetic fatty acid, or mixture thereof, typically having from about 6 to about 12 carbon atoms.
  • the fill materials described herein contain one or more sex hormones.
  • exemplary sex hormones include, but are not limited to, progesterone, alone or in combination with one or more other hormones.
  • the concentration of the sex hormone is from about 6% to about 50% by weight of the fill material, preferably from 7% to about 40% of the fill material, preferably from about 7% to about 25% by weight of the fill material, more preferably from about 7% to about 20%, more preferably from about 7% to about 15% by weight of the fill material.
  • the sex hormone is progesterone.
  • Progesterone is a C-21 steroid hormone involved in the female menstrual cycle, pregnancy (supports gestation) and embryogenesis of humans and other species.
  • the concentration of progesterone is from about 7% to about 15% by weight of the fill material, preferably from about 8% to about 12% by weight of the fill material, more preferably from about 9% to about 11% by weight of the fill material.
  • the dose of progesterone per capsule is preferably from about 100 mg to about 300 mg, more preferably from about 100 mg to about 200 mg. In one embodiment, the dose of progesterone is 100 mg, 200 mg, or 300 mg.
  • the carrier composition in which the sex hormone is dissolved contains one or more pharmaceutically acceptable fatty acids.
  • the one or more fatty acids have the general formula R—C( ⁇ O)—OH, wherein the R group contains from about 4 to about 20 carbons, preferably from about 8 to about 20 carbons, preferably from about 12 to about 20 carbons, more preferably from about 14 to about 20 carbons, most preferably from about 14 to about 18 carbons, and is fully saturated or contains one or more sites of unsaturation, in addition to the carbonyl group, such as carbon-carbon double bonds, carbon-carbon triple bonds, and combinations thereof.
  • Exemplary fatty acids include, but are not limited to, oleic acid, linoleic acid, myristoleic acid, palmitoleic acid, arachidonic acid, and combinations thereof.
  • Hydrophobic sex hormones such as progesterone
  • a carrier system containing fatty acids such as oleic acid.
  • concentration of the one or more fatty acids in the fill material is from about 60% to about 95% by weight of the fill material, preferably from about 60% to about 90% by weigh of the fill materials, more preferably from about 60% to about 85% by weight of the fill material, most preferably from about 60% to about 80% by weight.
  • the one or more fatty acids is oleic acid in a concentration from about 60% to about 95% by weight of the fill material, more preferably from about 65% to about 80% by weight of the fill material, most preferably from about 65% to about 75% by weight of the fill material.
  • the amount of the fatty acids can be expressed as weight percent of the carrier composition (i.e., the fill material absent the active pharmaceutical ingredient).
  • the concentration of the one or more fatty acids in the carrier composition is from about 60% to about 95% by weight of the carrier composition, preferably from about 65% to about 80% by weight of the carrier composition, more preferably from about 65% to 75% by weight of the carrier composition.
  • the carrier composition contains one or more pharmaceutically acceptable organic acids selected from C 1 to C 12 acids.
  • organic acids include, but are not limited to, lactic acid, acetic acid, glycolic acid, propionic acid, isobutyric acid, butyric acid, isovaleric acid, valeric acid, caproic acid, succinic acid, and combinations thereof.
  • the organic acid may be present at a concentration from about 1% to about 20% by weight of the fill material, preferably from 2% to 18% by weight of the fill material, preferably from about 3% to about 15% by weight of the fill material, more preferably from about 5% to about 12% by weight of the fill material, most preferably from about 6% to about 12% by weight of the fill material.
  • the amount of organic acid(s) can be expressed as weight percent of the carrier composition (i.e., the fill material absent the active pharmaceutical ingredient).
  • the concentration of the one or more organic acids in the carrier composition is from about 1% to about 20% by weight of the carrier composition, more preferably from 2% to 18% by weight of the carrier composition, and most preferably from about 3% to about 15% by weight of the carrier composition.
  • the carrier composition further contains one or more pharmaceutically acceptable alcohols and/or one or more pharmaceutically acceptable fatty acid esters.
  • Suitable alcohols include, but are not limited to, C 1 to C 6 alcohols.
  • Exemplary alcohols include, but are not limited to, pharmaceutically acceptable alcohols such as ethanol, isopropanol, isobutanol, butanol, t-butanol, glycerol, propylene glycol, and combinations thereof.
  • the concentration of the alcohol is from about 1% to about 20% by weight of the fill material, preferably from 2% to 18% by weight of the fill material, preferably from about 5 to about 15% by weight of the fill material, more preferably from about 6% to about 15% by weight of the fill material, most preferably from about 8% to about 15% by weight of the fill material.
  • the amount of alcohol(s) can be expressed as weight percent of the carrier composition (i.e., the fill material absent the active pharmaceutical ingredient).
  • the concentration of the one or more alcohols in the carrier composition is from about 1% to about 20% by weight of the carrier composition, more preferably from 2% to 18% by weight of the carrier composition, and most preferably from about 5% to about 15% by weight of the carrier composition.
  • Suitable fatty acid esters include, but are not limited to, pharmaceutically acceptable mono-, di- or tri-esters of medium or long chain fatty acids.
  • the fatty acid ester is a synthetic fatty acid ester of medium or long chain fatty acids or a mixture of synthetic fatty acid esters of medium or long chain fatty acids.
  • the fatty acid ester is a mixture of fatty acid esters which is not a natural vegetable oil.
  • Natural vegetable oils typically contain 50 to 95% by weight of glycerides of polyunsaturated fatty acids.
  • Exemplary vegetable oils include, but are not limited to, safflower oil, peanut oil, linseed oil, soybean oil, corn oil, and sunflower oil.
  • Suitable fatty acid esters include, but are not limited to, mono- and diglycerides of capric (C 10 ) and caprylic (C 8 ) acids, such as those available under the tradenames CAPMUL® and IMWITOR®.
  • CAPMUL® products are available from Abitec Corporation.
  • IMWITOR® products are available from Sasol.
  • esters include, but are not limited to, CAPMUL® MCM (glyceryl mono and dicaprate), CAPMUL® MCM C8 (glyceryl monocaprylate), CAPMUL® MCM C10 (glyceryl mono and dicaprate); IMWITOR® 988 (caprylic/capric glycerides), IMWITOR® 742 (caprylic/capric glycerides); mono-, di-, and triglycerides of coconut oil (IMWITOR® 928); glyceryl monooleate; glyceryl monolinoleate; propylene glycol esters (CAPMUL® PG-8 (propylene glycol monocaprylate), CAPRYOLTM 90 (propylene glycol monocaprylate 90%), CAPRYOLTM PGMC (propylene glycol caprylate), LABRAFACTM PG (propylene glycol dicaprylocaprate), LAUROGLYCOLTM 90 (propylene glycol monolaurate), LAUROGLYCOL
  • the concentration of the one or more esters is from about 1% to about 40% by weight of the fill material, preferably from about 5% to about 35% by weight of the fill material, preferably from about 10% to about 35% by weight of the fill material, more preferably from about 15% to about 35% by weight of the fill material, most preferably from about 20% to about 35% by weight of the fill material.
  • the amount of ester(s) can be expressed as weight percent of the carrier composition (i.e., the fill material absent the active pharmaceutical ingredient).
  • the concentration of the one or more esters in the carrier composition is from about 1% to about 40% by weight of the carrier composition, more preferably from 5% to 35% by weight of the carrier composition, and most preferably from about 10% to about 30% by weight of the carrier composition.
  • the carrier composition optionally contains one or more pharmaceutically acceptable additional co-solvents.
  • co-solvents include, but are not limited to, polyethoxylated glycerides, BrijTM 97 (polyoxyl 10 oleyl ether, oleth 10, polyethylene glycol monooleyl ether), Cremophor® A 25 (macrogol 25, cetostearyl ether, cetomacrogol), Cremophor® EL (polyoxyl 35 castor oil, glycerol polyethylene, glycol ricinoleate), Cremophor® RH 40 (polyoxyl 40 hydrogenated castor oil, glycerol polyethylene, glycol oxystearate), Labrafil® M 1944 (polyethylene glycol 300 oleic glycerides, oleoyl macrogol-6 glycerides), Labrafil® M 2125 (polyethylene glycol 300 linoleic glycerides, linoleoyl macrogol-6-
  • Antioxidants such as BHA and/or BHT may also be included in the carrier composition to prevent or minimize degradation of the formulation.
  • concentration of the antioxidant is typically from about 0.001% to about 2%, more preferably from about 0.00 to about 1%, most preferably from about 0.01 to about 0.5% by weight of the carrier.
  • compositions include, but are not limited to, pH stabilizers, thickeners/suspending agents, flavoring agents, sweeteners, and colorants.
  • the composition may further contain additional therapeutic, prophylactic, diagnostic, and/or nutraceutical agents.
  • suitable classes of active agents include, but are not limited to, analgesics, anti-inflammatory agents, antihelmintics, anti-arrhythmic agents, antibacterials, anticoagulants, antidepressants, antidiabetics, antiepileptics, antimalarials, antimigraine agents, antihistamines, antihypertensives, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants agents, antiprotozoal agents, antithyroid agents, antiviral agents, anxiolytic sedatives, astringents, beta adrenoceptor blocking agent, blood products and substitutes, cardiac tonotropic agents, corticosteroids, cough suppressants, diagnostic agents, diuretics, dopaminergics, haemostatics, lipid regulating agents, muscle relaxants, parasympathomimetics, prostaglandin
  • the capsule shells are prepared using one or more film forming polymers.
  • Suitable film forming polymers include natural polymers, such as gelatin, and synthetic film forming polymers, such as modified celluloses. Suitable modified celluloses include, but are not limited to, hydroxypropyl methyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, and cellulose acetate phthalate.
  • Hard or soft capsules can be used to administer the hormone. Hard shell capsules are typically prepared by forming the two capsule halves, filling one of the halves with the fill solution, and then sealing the capsule halves together to form the finished capsule. Soft gelatin capsules are typically prepared using a rotary die encapsulation process as described below.
  • Gelatin is the product of the partial hydrolysis of collagen. Gelatin is classified as either Type A or Type B gelatin. Type A gelatin is derived from the acid hydrolysis of collagen while Type B gelatin is derived from the alkaline hydrolysis of collagen. Traditionally, bovine bones and skins have been used as raw materials for manufacturing Type A and Type B gelatin while porcine skins have been used extensively for manufacturing Type A gelatin. In general, acid-processed gelatins form stronger gels than lime-processed gelatins of the same average molecular weight.
  • the capsules can be formulated as hard or soft gelatin capsules.
  • Capsules can be prepared from non-gelatin materials, such as carrageenan or modified celluloses.
  • Carrageenan is a natural polysaccharide hydrocolloid, which is derived from seaweed. It includes a linear carbohydrate polymer of repeating sugar units, without a significant degree of substitution or branching. Most, if not all, of the galactose units on a carrageenan molecule possess a sulfate ester group.
  • Suitable shell additives include plasticizers, opacifiers, colorants, humectants, preservatives, flavorings, and buffering salts and acids, and combinations thereof.
  • Plasticizers are chemical agents added to gelatin to make the material softer and more flexible. Suitable plasticizers include, but are not limited to, glycerin, sorbitol solutions which are mixtures of sorbitol and sorbitan, and other polyhydric alcohols such as propylene glycol and maltitol or combinations thereof.
  • Opacifiers are used to opacify the capsule shell when the encapsulated active agents are light sensitive. Suitable opacifiers include titanium dioxide, zinc oxide, calcium carbonate and combinations thereof.
  • Colorants can be used to for marketing and product identification/differentiation purposes. Suitable colorants include synthetic and natural dyes and combinations thereof.
  • Humectants can be used to suppress the water activity of the softgel. Suitable humectants include glycerin and sorbitol, which are often components of the plasticizer composition. Due to the low water activity of dried, properly stored softgels, the greatest risk from microorganisms comes from molds and yeasts. For this reason, preservatives can be incorporated into the capsule shell. Suitable preservatives include alkyl esters of p-hydroxy benzoic acid such as methyl, ethyl, propyl, butyl and heptyl esters (collectively known as “parabens”) or combinations thereof.
  • parabens alkyl esters of p-hydroxy benzoic acid
  • Flavorings can be used to mask unpleasant odors and tastes of fill formulations. Suitable flavorings include synthetic and natural flavorings. The use of flavorings can be problematic due to the presence of aldehydes which can cross-link gelatin. As a result, buffering salts and acids can be used in conjunction with flavorings that contain aldehydes in order to inhibit cross-linking of the gelatin.
  • the liquid fills can be incorporated into an enteric capsule, wherein the enteric polymer is a component of the capsule shell, as described in WO 2004/030658 to Banner Pharmacaps, Inc.
  • the enteric capsule shell is prepared from a mass comprising a film-forming polymer, an acid-insoluble polymer which is present in an amount making the capsule resistant to the acid within the stomach, an aqueous solvent, and optionally, one or more plasticizers and/or colorants.
  • suitable shell additives including opacifiers, colorants, humectants, preservatives, flavorings, and buffering salts and acids may be added.
  • Exemplary film-forming polymers can be of natural or synthetic origin. Natural film-forming polymers include gelatin and gelatin-like polymers. Other suitable natural film-forming polymers include shellac, alginates, pectin, and zeins. Synthetic film-forming polymers include hydroxypropyl methyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, cellulose acetate phthalate, and acrylates such as poly (meth)acrylate. The weight ratio of acid-insoluble polymer to film-forming polymer is from about 15% to about 50%. In one embodiment, the film forming polymer is gelatin.
  • Exemplary acid-insoluble polymers include cellulose acetate phthalate, cellulose acetate butyrate, hydroxypropyl methyl cellulose phthalate, algenic acid salts such as sodium or potassium alginate, shellac, pectin, acrylic acid-methylacrylic acid copolymers (available under the tradename EUDRAGIT® from Rohm America Inc., Piscataway, N.J. as a powder or a 30% aqueous dispersion; or under the tradename EASTACRYL®, from Eastman Chemical Co., Kingsport, Tenn., as a 30% dispersion).
  • the acid-insoluble polymer is EUDRAGIT® L100, which is a methacrylic acid/methacrylic acid methyl ester copolymer.
  • the acid-insoluble polymer is present in an amount from about 8% to about 20% by weight of the wet gelatin mass.
  • the weight ratio of acid-insoluble polymer to film-forming polymer is from about 15% to about 50%.
  • Hard and soft capsules are typically prepared from solutions or suspensions of the film forming polymer and the acid-insoluble polymer.
  • Suitable solvents include water, aqueous solvents, and organic solvents.
  • the solvent is water or an aqueous solvent.
  • Exemplary aqueous solvents include water or aqueous solutions of alkalis such as ammonia, sodium hydroxide, potassium hydroxide, ethylene diamine, hydroxylamine, tri-ethanol amine, or hydroalcoholic solutions of the same.
  • the alkali can be adjusted such that the final pH of the gelatin mass is less than or equal to 9.0, preferably less than or equal to 8.5, more preferably less than or equal to 8.0.
  • the alkali is a volatile alkali such as ammonia or ethylene diamine.
  • the water content of the capsule is from about 2% to about 10% by weight of the capsule, preferably from about 4% to about 8% by weight of the capsule.
  • plasticizers include glycerol, glycerin, sorbitol, polyethylene glycol, citric acid, citric acid esters such as triethylcitrate, polyalcohols with 3-6 carbons and combinations thereof.
  • the plasticizer to polymer (film forming polymer plus acid-insoluble polymer) ratio is from about 10% to about 50% of the polymer weight.
  • the fill material is prepared by dissolving the sex hormone, such as progesterone, in the carrier containing a fatty acid solvent, such as oleic acid.
  • the mixture of hormone and fatty acid may be heated to facilitate dissolution of the hormone.
  • the solution remains a liquid.
  • the fill is typically deaerated prior to encapsulation in a soft gelatin capsule.
  • Additional excipients including, but not limited to, co-solvents, antioxidants may be added to the mixture of the hormone and fatty acid. Again the mixture may be heated to facilitate dissolution of the excipients.
  • the progesterone is fully dissolved in the carrier of the present invention and remains so upon storage.
  • the main ingredients of the capsule shell are gelatin (or a gelatin substitute for non-gelatin capsules), plasticizer, and purified water.
  • the primary difference between soft and hard capsules is the amount of plasticizer present in the capsule shell.
  • Typical gel formulations contain (w/w) 40-50% gelatin, 20-30% plasticizer, and 30-40% purified water. Most of the water is subsequently lost during capsule drying.
  • the ingredients are combined to form a molten gelatin mass using either a cold melt or a hot melt process.
  • the prepared gel masses are transferred to preheated, temperature-controlled, jacketed holding tanks where the gel mass is aged at 50-60° C. until used for encapsulation.
  • the cold melt process involves mixing gelatin with plasticizer and chilled water and then transferring the mixture to a jacket-heated tank.
  • gelatin is added to the plasticizer at ambient temperature (18-22° C.).
  • the mixture is cooked (57-95° C.) under vacuum for 15-30 minutes to a homogeneous, deaerated gel mass.
  • Additional shell additives can be added to the gel mass at any point during the gel manufacturing process or they may be incorporated into the finished gel mass using a high torque mixer.
  • the hot melt process involves adding, under mild agitation, the gelatin to a preheated (60-80° C.) mixture of plasticizer and water and stirring the blend until complete melting is achieved. While the hot melt process is faster than the cold melt process, it is less accurately controlled and more susceptible to foaming and dusting.
  • Soft capsules are typically produced using a rotary die encapsulation process.
  • the gel mass is fed either by gravity or through positive displacement pumping to two heated (48-65° C.) metering devices.
  • the metering devices control the flow of gel into cooled (10-18° C.), rotating casting drums. Ribbons are formed as the cast gel masses set on contact with the surface of the drums.
  • the ribbons are fed through a series of guide rolls and between injection wedges and the capsule-forming dies.
  • a food-grade lubricant oil is applied onto the ribbons to reduce their tackiness and facilitate their transfer. Suitable lubricants include mineral oil, medium chain triglycerides, and soybean oil.
  • Fill formulations are fed into the encapsulation machine by gravity.
  • the soft capsules contain printing on the surface, optionally identifying the encapsulated agent and/or dosage.
  • the water content of the capsule is from about 2% to about 10% by weight of the capsule, preferably from about 4% to about 8% by weight of the capsule.
  • the enteric mass is typically manufactured by preparing an aqueous solution comprising a film-forming, water soluble polymer and an acid-insoluble polymer and mixing the solution with one or more appropriate plasticizers to form a gelatin mass.
  • the enteric mass can be prepared by using a ready-made aqueous dispersion of the acid-insoluble polymer by adding alkaline materials such as ammonium, sodium, or potassium hydroxides or other alkalis that will cause the acid-insoluble polymer to dissolve.
  • alkaline materials such as ammonium, sodium, or potassium hydroxides or other alkalis that will cause the acid-insoluble polymer to dissolve.
  • the plasticizer-wetted, film-forming polymer can then be mixed with the solution of the acid-insoluble polymer.
  • the mass can also be prepared by dissolving the acid-insoluble polymer or polymers in the form of salts of the above-mentioned bases or alkalis directly in water and mixing the solution with the plasticizer-wetted, film-forming polymer.
  • the mass is cast into films or ribbons using heat controlled drums or surfaces.
  • the fill material is encapsulated in a soft capsule using a rotary die.
  • the capsules are dried under controlled conditions of temperature and humidity.
  • the final moisture content of the shell composition is from about 2% to about 10% by weight of the capsule shell, preferably from about 4% to about 8% by weight by weight of the capsule shell.
  • release of the sex hormone from the capsule can be modified by coating the capsule with one or more modified release coatings, such as sustained release coatings, delayed release coatings, and combinations thereof.
  • Sex hormones can be used to treat a variety of conditions and disorders.
  • the sex hormone is progesterone.
  • Progesterone can be used to support pregnancy in Assisted Reproductive Technology (ART) cycles such as In-vitro Fertilization (IVF).
  • ART Assisted Reproductive Technology
  • IVF In-vitro Fertilization
  • Progesterone can be used to control anovulatory bleeding and is also used to prepare uterine lining in infertility therapy and to support early pregnancy. Patients with recurrent pregnancy loss due to inadequate progesterone production may receive progesterone.
  • Progesterone is also used for the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogen tablets and for treatment of secondary amenorrhea.
  • the dose of progesterone to be administered can be readily determined by the prescribing physician.
  • the dose of progesterone is from about 100 mg to about 300 mg, more preferably 100, 200, or 300 mg.
  • compositions described herein provide improved dissolution in aqueous media in vitro compared to formulations of hydrophobic drugs suspended in an oil, such as peanut oil.
  • the compositions described herein release at least about 10%, 20%, 30%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the drug in vitro after 5 minutes in 5% SDS in water or at least about 10%, 20%, 30%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the drug in vitro after 15 minutes in 0.5% SDS in water.
  • compositions described herein release at least about 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, or 70% of the drug in vitro in fed state simulated intestinal fluid (FeSSIF) after 24 hours.
  • FeSSIF fed state simulated intestinal fluid
  • the capsules described herein exhibit improved dissolution in aqueous media in vitro compared to formulations containing micronized progesterone suspended in an oil, such as peanut oil, such as commercially available formulations sold under the trademark PROMETRIUM®.
  • an oil such as peanut oil
  • PROMETRIUM® a commercially available formulations sold under the trademark PROMETRIUM®.
  • progesterone dissolved in fatty acid alone, or in combination with CAPMUL® PG-8 and ethanol release 90% of the progesterone after 15 minutes and 7 minutes, respectively, in 0.5% SDS and 5% SDS in water, respectively.
  • 5.5% of the progesterone was released after 1440 minutes from a two-piece hard shell capsule containing progesterone dissolved in oleic acid, Capmul® PG-8 and ethanol.
  • 3% of the progesterone was released from PROMETRIUM® during the same time period.
  • the capsules described herein should exhibit greater oral bioavailability and less interpatient and intrapatient invariability in vivo then formulations containing a micronized active agent, such as progesterone, suspended in an oil carrier, such as peanut oil. Further, the absence of oil-based carriers, such as peanut oil, should minimize or prevent allergic reactions.
  • Vials containing approximately 5 grams of Formulations 1-3 were kept at room temperature for 10 weeks. The solutions remained clear for at least 10 weeks.
  • Formulation 4 was prepared as follows. 594 g of oleic acid and 20.9 g of lactic acid were mixed together until the mixture was visually uniform. 100 g of progesterone powder was added to the mixture and stirred at 60 rpm until completely wetted. 302.3 g of CAPMUL® PG-8 (Abitech, NF grade) was added with stirring and the stirring was continued for at least 15 minutes, until a clear solution was obtained.
  • Formulation 5 was prepared as follows. 596 g of oleic acid and 22.6 g of lactic acid were mixed together until the mixture was visually uniform. 100 g of progesterone powder was added to the mixture and stirred at 60 rpm until completely wetted. 253 g of CAPMUL® PG-8 was added with stirring and the stirring was continued for at least 15 minutes, until a clear solution was obtained. 49.7 g of ethanol was added to the mixture and stirred for another 10 minutes.
  • Formulations 4 and 5 were divided into portions of about 5 grams each, which were added to 20 ml clear glass scintillation vials with proper capping. The vials were put into a 40° C. oven for three weeks. All the solutions remained clear.
  • Vials containing aliquots of formulations 4 and 5 were kept at room temperature and remained clear for at least 10 weeks.
  • the progesterone formulation prepared in Example 3 was divided into portions of about 5 grams each, which were added to 20 ml glass scintillation vials with caps. The vials were put into an oven set at 65° C. One set was heated for 7 days. The samples were assayed for progesterone content by HPLC, using a procedure adapted from the USP method.
  • the chromatographic conditions were as follows:
  • the excipients used in Formulation 5 are compatible with progesterone, without significant loss of potency, even after one week at 65° C., compared to samples stored at room temperature.
  • Example 3 The progesterone solution of Example 3 (Formulation 5) was added to empty hard gelatin capsules (Size Number 1, made by Eli Lilly and Company, Indianapolis, Ind.). Three capsules are filled with 1.0 grams of the fill solution, which contained approximately 83 mg progesterone.
  • Example 1 The progesterone solution of Example 1 (Formulation 1) and Example 3 (Formulation 5) were each encapsulated in softgel capsules.
  • Bovine gelatin extracted from bones, was mixed with the appropriate amount of glycerin and water. The mixture was heated to 70° C. under continuous mixing for 24 hours, and then cooled to about 60° C. The gelatin mixture was added to the containers of an encapsulation machine. The ribbon thickness was maintained at 0.030 inches. The die size was 22 oblong. The fill weight was 1021 mg and the capsules contained approximately 100 mg of progesterone. The softgel capsules were dried for two weeks to obtain a hardness of 9 Newtons.
  • Dissolution tests, assays, and stability tests were carried out on the softgel capsules.
  • phase stability e.g., precipitation of the drug substance in the carrier over a prolonged period of time
  • the capsules were stored at room temperature for up to 8 months and ten days.
  • the capsules were cut open and the fill materials observed visually. No precipitate or insoluble materials were observed in either of the formulations over the time periods observed.
  • Dissolution studies were performed using USP Dissolution Apparatus II (paddle @100 rpm) using various dissolution media containing various levels of sodium dodecyl sulfate (SDS) in de-aerated water as described below.
  • the volume of the dissolution medium used was 900 mL. All dissolution experiments were carried out at 37° C. At pre-determined time intervals (5, 15, 30, 45, 60, 120, 180, 240, 300, and 1440 minutes) aliquots were taken and assayed.
  • the samples were assayed for progesterone concentration in the dissolution media by HPLC using an Agilent ChemStation under the conditions described in Example 4. The results are shown in FIGS. 1-3 .
  • FIG. 1 The dissolution study in an aqueous medium containing 5% SDS ( FIG. 1 ) shows the complete dissolution of the formulation described in Example 3 (Formulation 5) within 5 minutes, while PROMETRIUM® takes almost 24 hours to reach the same degree of dissolution.
  • Example 1 The results of the dissolution study performed in an aqueous medium containing 0.5% SDS are shown in FIG. 2 .
  • the formulation of Example 1 (Formulation 1) was compared to commercially available progesterone PROMETRIUM®. This formulation was shown to have much faster onset and fuller dissolution, compared to PROMETRIUM®.
  • Example 5 A study was also performed using deareated water only (no surfactant). The formulation of Example 3 (Formulation 5) was compared to commercially available progesterone PROMETRIUM®. The results are shown in FIG. 3 . Formulation 5 has a much faster dissolution onset and a higher overall dissolution rate. After 1440 minutes, Formulation 5 released twice as much progesterone than PROMETRIUMTM.
  • the dissolution was performed at 37° C. using USP Apparatus H (paddle) at 50 rpm in 1000 ml of the dissolution medium.
  • the dissolution results are shown in FIG. 4 .
  • the amount of progesterone released from Formulation 5 in FeSSIF medium was about 4 to 5 times higher than that released from PROMETRIUM® capsules.
  • the cumulative release at the end of 24 hours from Formulation 5 was about 51% versus less than about 10% from PROMETRIUM®.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US12/752,629 2009-04-06 2010-04-01 Progesterone solutions for increased bioavailability Active 2032-08-15 US9011908B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/752,629 US9011908B2 (en) 2009-04-06 2010-04-01 Progesterone solutions for increased bioavailability

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16686609P 2009-04-06 2009-04-06
US12/752,629 US9011908B2 (en) 2009-04-06 2010-04-01 Progesterone solutions for increased bioavailability

Publications (2)

Publication Number Publication Date
US20100255085A1 US20100255085A1 (en) 2010-10-07
US9011908B2 true US9011908B2 (en) 2015-04-21

Family

ID=42173978

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/752,629 Active 2032-08-15 US9011908B2 (en) 2009-04-06 2010-04-01 Progesterone solutions for increased bioavailability

Country Status (2)

Country Link
US (1) US9011908B2 (fr)
WO (1) WO2010117873A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11980691B2 (en) 2018-03-15 2024-05-14 R.P. Scherer Technologies, Llc Enteric softgel capsules

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US20110312928A1 (en) * 2010-06-18 2011-12-22 Lipocine Inc. Progesterone Containing Oral Dosage Forms and Related Methods
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
HRP20211377T1 (hr) 2011-11-23 2022-01-07 Therapeuticsmd, Inc. Prirodne kombinirane hormonske supstitucijske formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) * 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2015179782A1 (fr) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Formulations d'hormones substitutives combinées naturelles et traitement hormonal substitutif
US20150366814A1 (en) 2014-06-23 2015-12-24 Banner Life Sciences Llc All-natural enteric soft capsules comprising active ingredients
CA2951284A1 (fr) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Creme transdermique
EP3053598A1 (fr) 2015-02-06 2016-08-10 Faes Farma, S.A. Capsules molles de calcifédiol
EP3310359B1 (fr) 2015-06-22 2024-12-18 Lipocine Inc. Compositions orales contenant un ester de 17-hydroxyprogestérone et procédés s'y rapportant
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017105512A1 (fr) 2015-12-18 2017-06-22 Proinvet Innovations S.A. Formulations et procédés de commande du cycle de reproduction et de l'ovulation
WO2017173044A1 (fr) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Compositions d'hormones stéroïdes dans des huiles à chaîne moyenne
MX2018011705A (es) 2016-04-01 2019-06-10 Therapeuticsmd Inc Composicion farmaceutica de hormona esteroide.

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4701327A (en) * 1984-05-15 1987-10-20 Nippon Kayaku Kabushiki Kaisha Etoposide soft capsules
US4963540A (en) 1986-04-16 1990-10-16 Maxson Wayne S Method for treatment of premenstrual syndrome
WO1995024893A1 (fr) 1994-03-16 1995-09-21 R.P. Scherer Limited Systemes d'administration s'appliquant a des medicaments hydrophobes
WO1997009978A1 (fr) 1995-09-13 1997-03-20 Morten Sloth Weidner Utilisation d'esters de polyols pour augmenter la biodisponibilite orale de substances medicamenteuses, nouveaux esters et compositions pharmaceutiques les contenant
WO1997040823A1 (fr) 1996-04-26 1997-11-06 R.P. Scherer Limited Preparation pharmaceutique orale contenant des hormones sexuelles
US5874106A (en) * 1996-03-12 1999-02-23 Novartis Finance Corporation Filled gelatin capsules
WO1999008666A2 (fr) 1997-08-19 1999-02-25 Glaxo Group Limited Composition pharmaceutique
US6638522B1 (en) * 1998-12-11 2003-10-28 Pharmasolutions, Inc. Microemulsion concentrate composition of cyclosporin
WO2004030658A1 (fr) 2002-10-01 2004-04-15 Banner Pharmacaps, Inc. Composition enterique pour la fabrication d'un enrobage de capsule molle
WO2005072686A1 (fr) 2004-01-20 2005-08-11 Stiefel Laboratories, Inc. Compositions de capsules molles dermatologiques
WO2006102157A1 (fr) 2005-03-21 2006-09-28 Ivax Pharmaceuticals S.R.O. Inhibiteur de cristallisation et son utilisation dans des capsules de gelatine
US20060257472A1 (en) * 2003-09-29 2006-11-16 Novo Nordisk Femcare Ag Stability of progestogen formulations
US20070053869A1 (en) * 2005-09-02 2007-03-08 Yuichi Sugiyama Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4701327A (en) * 1984-05-15 1987-10-20 Nippon Kayaku Kabushiki Kaisha Etoposide soft capsules
US4963540A (en) 1986-04-16 1990-10-16 Maxson Wayne S Method for treatment of premenstrual syndrome
US6096338A (en) * 1994-03-16 2000-08-01 R. P. Scherer Corporation Delivery systems for hydrophobic drugs
WO1995024893A1 (fr) 1994-03-16 1995-09-21 R.P. Scherer Limited Systemes d'administration s'appliquant a des medicaments hydrophobes
EP0750495A1 (fr) 1994-03-16 1997-01-02 R.P. Scherer Limited Systemes d'administration s'appliquant a des medicaments hydrophobes
US5645856A (en) 1994-03-16 1997-07-08 R. P. Scherer Corporation Delivery systems for hydrophobic drugs
WO1997009978A1 (fr) 1995-09-13 1997-03-20 Morten Sloth Weidner Utilisation d'esters de polyols pour augmenter la biodisponibilite orale de substances medicamenteuses, nouveaux esters et compositions pharmaceutiques les contenant
US5874106A (en) * 1996-03-12 1999-02-23 Novartis Finance Corporation Filled gelatin capsules
WO1997040823A1 (fr) 1996-04-26 1997-11-06 R.P. Scherer Limited Preparation pharmaceutique orale contenant des hormones sexuelles
WO1999008666A2 (fr) 1997-08-19 1999-02-25 Glaxo Group Limited Composition pharmaceutique
US6638522B1 (en) * 1998-12-11 2003-10-28 Pharmasolutions, Inc. Microemulsion concentrate composition of cyclosporin
WO2004030658A1 (fr) 2002-10-01 2004-04-15 Banner Pharmacaps, Inc. Composition enterique pour la fabrication d'un enrobage de capsule molle
US20060257472A1 (en) * 2003-09-29 2006-11-16 Novo Nordisk Femcare Ag Stability of progestogen formulations
WO2005072686A1 (fr) 2004-01-20 2005-08-11 Stiefel Laboratories, Inc. Compositions de capsules molles dermatologiques
WO2006102157A1 (fr) 2005-03-21 2006-09-28 Ivax Pharmaceuticals S.R.O. Inhibiteur de cristallisation et son utilisation dans des capsules de gelatine
US20070053869A1 (en) * 2005-09-02 2007-03-08 Yuichi Sugiyama Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
International Search Report PCT/US2010/029625, mailed Mar. 3, 2011.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11980691B2 (en) 2018-03-15 2024-05-14 R.P. Scherer Technologies, Llc Enteric softgel capsules

Also Published As

Publication number Publication date
WO2010117873A2 (fr) 2010-10-14
US20100255085A1 (en) 2010-10-07
WO2010117873A3 (fr) 2011-04-28

Similar Documents

Publication Publication Date Title
US9011908B2 (en) Progesterone solutions for increased bioavailability
US10639375B2 (en) Progesterone formulations
US11865179B2 (en) Progesterone formulations having a desirable PK profile
US20200323881A1 (en) Soluble estradiol capsule for vaginal insertion
US20200230050A1 (en) Vaginal inserted estradiol pharmaceutical compositions and methods
JP6285866B2 (ja) 天然複合ホルモン補充製剤および療法
EP0904064B1 (fr) Preparation pharmaceutique orale contenant des hormones sexuelles
RU2740059C2 (ru) Капсулы с растворимым эстрадиолом для интравагинального введения
US10286077B2 (en) Steroid hormone compositions in medium chain oils
JP4354667B2 (ja) 避妊薬としての使用へのエチニルエストラジオールとドロスピレノンの医薬用組合せ
US20140370084A1 (en) Estradiol formulations and therapies
KR20080009201A (ko) 소수성 약물의 약물전달시스템 및 이를 포함하는 조성물
BR112017010657B1 (pt) Cápsulas moles de calcifediol
US20180221387A1 (en) Composition and method for oral delivery of androgen prodrugs
US20180078568A1 (en) Pharmaceutical composition and methods
JP7654561B2 (ja) 浸透性が低いタンパク質、ペプチド、及び小分子の経口送達用の製剤
KR20160137597A (ko) 프로게스테론 제형
US20210353573A1 (en) A soft-gel capsule formulation, method of manufacture and use thereof
US20210121480A1 (en) Stable pharmaceutical compositions containing estradiol and progesterone for oral administration
US20250360079A1 (en) Vaginal inserted estradiol pharmaceutical compositions and methods
JP6680672B2 (ja) 膣挿入されるエストラジオール薬学的組成物及び方法
WO2022170398A1 (fr) Formulations pour biodisponibilité améliorée du fenrétinide
WO2016105465A1 (fr) Compositions orales pour composés insolubles
HK40015588B (en) Progesterone formulations
US20150250751A1 (en) Pharmaceutical compositions of diclofenac or salts thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: BANNER PHARMACAPS, INC., NORTH CAROLINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIU, ZHI;GOSANGARI, SAUJANYA L.;TOOPS, DANA S.;AND OTHERS;SIGNING DATES FROM 20100412 TO 20100421;REEL/FRAME:024527/0357

AS Assignment

Owner name: MORGAN STANLEY SENIOR FUNDING INC., AS COLLATERAL

Free format text: SECURITY AGREEMENT;ASSIGNOR:BANNER PHARMACAPS INC.;REEL/FRAME:029481/0962

Effective date: 20121214

AS Assignment

Owner name: UBS AG, STAMFORD BRANCH, AS COLLATERAL AGENT, CONN

Free format text: SECURITY INTEREST;ASSIGNOR:BANNER PHARMACAPS INC.;REEL/FRAME:032403/0790

Effective date: 20140311

AS Assignment

Owner name: BANNER PHARMACAPS INC., NORTH CAROLINA

Free format text: TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENT RIGHTS;ASSIGNOR:MORGAN STANLEY SENIOR FUNDING, INC.;REEL/FRAME:032745/0454

Effective date: 20140311

AS Assignment

Owner name: BANNER LIFE SCIENCES LLC, NORTH CAROLINA

Free format text: CHANGE OF NAME;ASSIGNOR:BANNER PHARMACAPS INC.;REEL/FRAME:034359/0872

Effective date: 20141101

AS Assignment

Owner name: UBS AG, STAMFORD BRANCH, AS COLLATERAL AGENT, CONN

Free format text: SECURITY INTEREST;ASSIGNOR:BANNER LIFE SCIENCES LLC;REEL/FRAME:035133/0328

Effective date: 20150305

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: BANNER PHARMACAPS INC., NORTH CAROLINA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:UBS AG, STAMFORD BRANCH;REEL/FRAME:036224/0623

Effective date: 20150731

Owner name: BANNER LIFE SCIENCES LLC, NORTH CAROLINA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:UBS AG, STAMFORD BRANCH;REEL/FRAME:036224/0623

Effective date: 20150731

Owner name: BANNER LIFE SCIENCES LLC, NORTH CAROLINA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:UBS AG, STAMFORD BRANCH;REEL/FRAME:036239/0188

Effective date: 20150731

CC Certificate of correction
AS Assignment

Owner name: BANNER LIFE SCIENCES LLC, NORTH CAROLINA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVEYANCE PREVIOUSLY RECORDED AT REEL: 034359 FRAME: 872. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:BANNER PHARMACAPS INC.;REEL/FRAME:037055/0101

Effective date: 20141121

AS Assignment

Owner name: PATHEON SOFTGELS INC, NORTH CAROLINA

Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:BANNER LIFE SCIENCES LLC;REEL/FRAME:043032/0619

Effective date: 20170622

AS Assignment

Owner name: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS SUCCES

Free format text: NOTICE OF SUCCESSION OF AGENCY FOR PATENT SECURITY INTEREST PREVIOUSLY RECORDED AT REEL/FRAME (032403/0790);ASSIGNOR:UBS AG, STAMFORD BRANCH, AS PRIOR AGENT;REEL/FRAME:043173/0005

Effective date: 20170620

AS Assignment

Owner name: BANNER PHARMACAPS INC., NORTH CAROLINA

Free format text: RELEASE (REEL 032403 / FRAME 0790);ASSIGNOR:CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH;REEL/FRAME:044038/0028

Effective date: 20170921

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8